Niraparib (Zejula▼): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment

Blood pressure should be monitored at least weekly for the first 2 months, then monthly for the first year and periodically thereafter, as there have been reports of severe hypertension (including hypertensive crisis) and PRES as early as within the first month of treatment.

Source:

Medicines and Healthcare products Regulatory Agency